Physician profile
Douglas A Nelson
NPI 1497720049
$7,837.56
in general payments reported to CMS, 2019-2025
20 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $23.26 · 2021: $11.92 · 2022: $1,575 · 2023: $925 · 2024: $3,038 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,342 · Food and Beverage: $1,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,341.68 |
| Food and Beverage | $1,695.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,037.83 | 2019-2025 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $1,593.27 | 2019-2022 | |
| Taiho Oncology, INC. | $1,130.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $531.68 | 2023 | |
| Genentech, INC. | $525.06 | 2023-2024 | Tecentriq, Avastin, Tecentriq Hybreza |
| E.R. Squibb & Sons, L.L.C. | $191.84 | 2023-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $184.98 | 2024-2025 | Fruzaqla |
| Glaxosmithkline, LLC. | $121.12 | 2024 | Jemperli |
| Comsort, INC | $100.00 | 2019 | |
| Amgen INC. | $97.92 | 2024 | Vectibix |
| Ipsen Biopharmaceuticals, INC | $71.65 | 2025 | Onivyde |
| Histosonics, INC. | $71.35 | 2024 | |
| Seagen INC. | $53.36 | 2023 | Adcetris |
| Celgene Corporation | $42.46 | 2019-2025 | Opdivo |
| Daiichi Sankyo INC. | $23.26 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $21.28 | 2019 | |
| Tempus Ai, INC | $14.42 | 2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.